Biotech firm maintains 2026 net product revenue guidance while targeting late-2024 data for its experimental treatment cohort.
Sarepta Therapeutics reaffirmed its 2026 net product revenue guidance of $1.2 billion to $1.4 billion. The company cited ongoing commercial performance and pipeline progress as key drivers for the outlook.
The guidance remains unchanged from prior disclosures, aligning with analyst expectations. Sarepta also set a year-end target for releasing data from Cohort 8 of its gene therapy program, a closely watched milestone for investors.
Shares showed muted reaction in after-hours trading, reflecting investor focus on upcoming clinical data rather than revenue projections.